MedTrace Logo

Localising Occult Prostate Cancer Metastases With Advanced Imaging TEchniques

NCT02935816 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2016-10-18

No results posted yet for this study

Summary

The investigator prospectively compare diagnostic concordance of whole body multi---parametric Magnetic Resonance Imaging (MRI) with current conventional multi---modality reference standard imaging (CT scan, isotope bone scan +/--- PET---CT scan) for staging of prostate cancer patients with biochemical relapse following external beam radiotherapy or brachytherapy of locally advanced prostate cancer.

Conditions

Interventions

RADIATION

Whole body MRI

We have developed and assessed the feasibility of performing whole---body multi---parametric MRI for staging metastatic disease. We hypothesize that a whole body multi---parametric MRI will be more sensitive and specific than conventional imaging staging for detection of metastatic disease in patients with biochemical failure following local therapies. We therefore propose a comparative trial of conventional imaging verses whole---body multi---parametric MRI within this population of men

Sponsors & Collaborators

  • University College, London

    lead OTHER

Principal Investigators

  • Shonit Punwani · Centre for Medical Imaging

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02935816 on ClinicalTrials.gov